Details
Category: Volume 07 Issue 09 September 2019
Hits: 4105

Title: Efficacy of Combination of Metolazone and Torsemide in Type 2 and 4 Cardiorenal Syndrome

Authors: Dorchhom Khrime, Alok Kumar, Nitin Bansal

 DOI: https://dx.doi.org/10.18535/jmscr/v7i9.80

Abstract

  

Background: There is paucity of literature on use of combination of metolazone and torsemide in patients of type 2 and type 4 cardiorenal syndrome. These patients develop resistance to loop diuretics and fluid overload one of the most important issue. Therefore optimization of diuretic use is crucial for successful management of such patients. We undertook this study to look for efficacy and safety of using metolazone on top of torsemide in patients of type 2 and type 4 cardiorenal syndrome.

Methods: We did retrospective analysis of our patients with type 2 and type 4 cardiorenal syndrome. All of them were started on torsemide 100 mg intravenous bolus and 5 mg metolazone was added later. There hourly urine output , weight loss and BP was recorded. Their demographic data and laboratory parameters were recorded. Appropriate statistics was applied.

Results: We had cohort of 37 patients. They had man age of 56.4±8.5 years. Study population included 22 males and 15 females. There were 54% patients with CRS type 2 and 46% patients with type 4 CRS. 33 patients responded to addition of metolazone. Four patients needed dialysis. Patients had mean weight loss of 2.3± 1.3 kg after 3 days. Hypokalemia was seen in seven patients. Hypotension was also observed in n=2 patients. There was significant increase in urine output. NYHA class also improved in 33 patients.

Conclusion: Combination of metolazone and torsemide was effective and safe in majority of our patients as reflected by increase in urine output and improvement in dyspnea.

References

  1. Lullo LD, Bellasi A, Barbera V, Russo D, Russo L, Lario D Bi, Cozzalina M, Ronco C, Pathophysiology of cardio renal syndrome 1-5 :an update. Indian Heart J.2017;69:255-2651.
  2. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, et al. (2003) Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: : A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 108(17): 2154-2169.2.
  3. Weir MR (2011) Recognizing the Link between Chronic Kidney Disease and Cardiovascular Disease. Am J Manag Care.; 17: S396-S402.
  4. Ronco C. The cardiorenal syndrome: basis and common ground for a multidisciplinary patient-oriented therapy. Cardiorenal Med. 2011;1:3–4.
  5. Hanada S, Takewa Y, MizunoT, TsukiyanT, TaenakaY, Tatsumi E. Effectof the technique for assisting renal blood circulation on ischemic kidney in acute cardiorenal syndrome. J Artif Organs. 2012;15:140–145.
  6. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimatinghemodynamicsinchronicheartfailure.JAMA.1989;261:884–888.
  7. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589–596.
  8. Uthoff H, Breidthardt T, Klima T, et al. Central venous pressure and impaired renal function in patients with acute heart failure. Eur J Heart Fail. 2011;13:432–439.
  9. Braam B, Cupples WA, Joles JA, Gaillard C. Systemic arterial and venous determinants of renal hemodynamics in congestive heart failure. Heart Fail Rev. 2012;17:161–175.
  10. Sica DA (2011) Diuretic use in renal disease. Nat Rev Nephrol 8(2): 100-109.
  11. Smiley JW, Onesti G, Swartz C (1972) The acute effects of Metolazone on electrolyte and acid excretion in man. Clin Pharmacol Ther 13(3): 336-342.
  12. Sica DA (2006) Diuretic-related side effects: development and treatment. J Clin Hypertens 6(9): 532-540
  13. Smiley JW, Onesti G, Swartz C (1972) The acute effects of Metolazone on electrolyte and acid excretion in man. Clin Pharmacol Ther 13(3): 336-342
  14. Bataclan RPa, Alonso RSa. Metolazone and Furosemide Combination in Cardiorenal Syndrome: Short-Term Safety and Efficacy Among Admitted Patients in a Tertiary Hospital. JOJ uro & nephron. 2019; 6(3): 001-006
  15. Desai N, Singh RK, Adiaga S (2007) Diuretic Efficacy and Tolerability of Metolazone in Chronic Congestive Cardiac failure- A Clinical Trial Report Indian Medical Gazette.8:452-455.
  16. Ng TMH, Konopka E, Hyderi AF, Hshieh S, Tsuji Y, et al. (2013) Metolazone-Based Diuretic Regimens to Furosemide in Acute Heart Failure. J Cardiovasc Pharmacol Ther 18(4): 343-351.
  17. Vanky, M. Broquist, R. Svedjeholm (1997) Addition of a thiazide: an effective remedy for furosemide resistance after cardiac operations. Ann Thorac Surg, 63 : 993-997   
  18. H.A. Cooper, D.L. Dries, C.E. Davis, Y.L. Shen, M.J. Domanski (1999)Diuretics and risk of arrhythmic  death in patients with left ventricular dysfunction Circulation 100: 1311-1315

Corresponding Author

Dr Alok Kumar

Assistant Professor and Head, Department of Nephrology Shri Guru Ram Rai Institute of Medical and Health Sciences Dehradun Uttarakhand, India